- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00339131
ULTRATRACE Iobenguane I 131 in Patients With Malignant Pheochromocytoma, Paraganglioma, or Metastatic Carcinoid
October 7, 2011 updated by: Molecular Insight Pharmaceuticals, Inc.
Phase 1 Study Evaluating the Safety, Distribution, Metabolism, and Radiation Dosimetry of ULTRATRACE Iobenguane I 131 in Patients With Malignant Pheochromocytoma/Paraganglioma or Metastatic Carcinoid
The purpose of this study is to test the safety of a drug called Ultratrace iobenguane I 131 that has radioactivity, to measure how long it takes for the drug to be absorbed and passed out of the body, and to measure how much radioactivity is absorbed into different tissues of the body.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Iobenguane, which is also known as MIBG, has been used in many patients who have types of cancers caused by what are known as neuroendocrine tumors, such as pheochromocytoma, paraganglioma, and carcinoid.
Iobenguane is absorbed by neuroendocrine tumor cells.
The radioactive portion of the study drug, Ultratrace iobenguane, is a form of iodine called I 131.
The I 131 is absorbed into the tumor with the iobenguane, and the radioactivity should kill the tumors.
The type of iobenguane being studied is called Ultratrace because of the new way in which this form of iobenguane is made.
This study is the first time in which Ultratrace iobenguane will be given to patients.
The purpose of the study is to give a low dose of iobenguane just to find out if the drug is safe, to measure how long it takes the drug to be absorbed and passed out of the body, and to see how much radioactivity is absorbed by different types of tissues of the body.
Study Type
Interventional
Enrollment (Anticipated)
24
Phase
- Phase 1
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
Patients will enter one of two study arms depending on their type of neuroendocrine tumor.
Arm P patients must:
- Have a biochemical or histopathological diagnosis of either adrenal pheochromocytoma or extra-adrenal paraganglioma (biochemical diagnosis includes plasma-free metanephrines and 24-hour urine test for catecholamines/metanephrines)
- Disease is metastatic or has recurred following surgery
- Have a CT scan performed (for later measurement of disease volume by the core lab) within 90 days of the administration of study drug without any interventions between CT and iobenguane I 131 imaging.
Arm C patients must:
- Have a histopathological diagnosis of carcinoid, or by plasma chromogranin A (CgA) and 24-hour urine test for 5-hydroxyindole-acetic-acid (5HIAA)
- Disease is metastatic or has recurred following surgery
- Have a CT scan performed (for the later measurement of disease volume by the core lab) within 90 days of the administration of study drug without any interventions between CT and iobenguane I 131 imaging.
All patients in Arm P and Arm C must also meet each of the following inclusion criteria:
- Provide written informed consent and are willing to comply with protocol requirements
- Are at least 18 years of age
- If female, then not of childbearing potential as documented by history (e.g., tubal ligation or hysterectomy) or is post menopausal with a minimum 1 year without menses
- If female of childbearing potential, has a negative serum HCG pregnancy test within 24 hours prior to receiving iobenguane I 131
- If female of childbearing potential, agrees to use an acceptable form of birth control, defined as abstinence or use of IUD, oral contraceptive, barrier and spermicide, or hormonal implant, throughout the study period
Exclusion Criteria:
• Females who are nursing
- Documented history of significant allergy that required medical intervention to shellfish, X-ray contrast media , iodine/iodides, or iobenguane
- Administered a radioisotope within 5 effective half-lives of that radioisotope prior to study enrollment
- Karnofsky performance status is < 60
- Serum creatinine > 2.0 mg/dL
- Total bilirubin > 1.5 times the upper limit of normal
- AST/SGOT or ALT/SGPT > 3 times the upper limit of normal
- Has received an investigational compound and/or medical device within 30 days before admission into this study
- Has any medical condition or other circumstances which would significantly decrease the chances of obtaining reliable data, achieving study objectives, or completing the study and/or post dose follow-up examinations
- Is determined by the Investigator that the patient is clinically unsuitable for the study
- Has received a medication which inhibits uptake of iobenguane I 131 within 2 weeks prior to the administration of study drug. Patients must not have taken tricyclic antidepressants or related drugs within 6 weeks prior to enrollment.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: DIAGNOSTIC
- Allocation: NON_RANDOMIZED
- Interventional Model: SINGLE_GROUP
- Masking: NONE
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
whole body imaging immediately post-dose
|
whole body imaging 1 hour post-dose
|
whole body imaging 3 hours post-dose
|
whole body imaging 6 hours post-dose
|
whole body imaging 24 hours post-dose
|
whole body imaging 48 hours post-dose
|
whole body imaging 120 hours post-dose
|
Secondary Outcome Measures
Outcome Measure |
---|
blood and urine samples pre-dose
|
blood and urine samples immediately post-dose
|
blood and urine samples 1 hour post-dose
|
blood and urine samples 3 hours post-dose
|
blood and urine samples 6 hours post-dose
|
blood and urine samples 24 hours post-dose
|
blood and urine samples 48 hours post-dose
|
blood and urine samples 120 hours post-dose
|
continuous urine samples at intervals of 0-6 hours, 6-24 hours, 24-48 hours, 48-72 hours, 72-96 hours and 96-120 hours post-dose
|
monitoring for adverse events starting when the patient consents to be in the study until 2 weeks post-dose
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Ralph E Coleman, MD, Duke University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
June 1, 2006
Study Completion (ACTUAL)
January 1, 2007
Study Registration Dates
First Submitted
June 17, 2006
First Submitted That Met QC Criteria
June 17, 2006
First Posted (ESTIMATE)
June 20, 2006
Study Record Updates
Last Update Posted (ESTIMATE)
October 12, 2011
Last Update Submitted That Met QC Criteria
October 7, 2011
Last Verified
October 1, 2011
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Adenocarcinoma
- Carcinoma
- Neoplasms, Glandular and Epithelial
- Neuroectodermal Tumors
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Nerve Tissue
- Neuroendocrine Tumors
- Carcinoid Tumor
- Pheochromocytoma
- Paraganglioma
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Radiopharmaceuticals
- 3-Iodobenzylguanidine
Other Study ID Numbers
- MIP-IB11
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pheochromocytoma
-
National Cancer Institute (NCI)RecruitingMetastatic Adrenal Gland Pheochromocytoma | Metastatic Paraganglioma | Unresectable Adrenal Gland Pheochromocytoma | Unresectable Paraganglioma | Advanced Adrenal Gland Pheochromocytoma | Advanced Paraganglioma | Stage III Adrenal Gland Pheochromocytoma and Sympathetic Paraganglioma AJCC v8 | Stage...United States
-
Peking Union Medical College HospitalRecruitingPheochromocytoma, Metastatic | Paraganglioma, Malignant | Pheochromocytoma MalignantChina
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingMetastatic Adrenal Gland Pheochromocytoma | Locally Advanced Paraganglioma | Metastatic Paraganglioma | Unresectable Adrenal Gland Pheochromocytoma | Unresectable Paraganglioma | Regional Adrenal Gland PheochromocytomaUnited States
-
Peking Union Medical College HospitalRecruitingUltrasonography | Pheochromocytoma, Metastatic | Paraganglioma, Malignant | Pheochromocytoma MalignantChina
-
Abramson Cancer Center of the University of PennsylvaniaCompletedUnresectable Paraganglioma | Recurrent Pheochromocytoma | Advanced Metastatic Paraganglioma | Advanced Metastatic Pheochromocytoma | Recurrent Paraganglioma | Unresectable PheochromocytomaUnited States
-
Peking Union Medical College HospitalCompletedPheochromocytoma, Metastatic | Paraganglioma, Malignant | Pheochromocytoma MalignantChina
-
Mayo ClinicNational Cancer Institute (NCI)CompletedMetastatic Adrenal Gland Pheochromocytoma | Malignant Adrenal Gland Pheochromocytoma | Malignant ParagangliomaUnited States
-
Peking Union Medical College HospitalRecruitingParaganglioma, Extra-Adrenal | Malignant Adrenal Gland Pheochromocytoma | Malignant Paraganglioma | Pheochromocytoma, Metastatic | Paraganglioma, MalignantChina
-
Kunwu Yan,MMCompletedHemodynamic | Adrenal Pheochromocytoma
-
National Cancer Institute (NCI)TerminatedParaganglioma | Metastatic Adrenal Gland Pheochromocytoma | Recurrent Adrenal Gland Pheochromocytoma | Extra-Adrenal ParagangliomaUnited States, Singapore, Hong Kong
Clinical Trials on Ultratrace iobenguane I 131
-
Molecular Insight Pharmaceuticals, Inc.CompletedPheochromocytoma | ParagangliomaUnited States
-
Molecular Insight Pharmaceuticals, Inc.WithdrawnNeuroblastomaUnited States, Canada
-
Jubilant DraxImage Inc.AvailableNeuroblastoma | Pheochromocytoma | ParagangliomaUnited States
-
Molecular Insight Pharmaceuticals, Inc.CompletedNeuroblastomaUnited States
-
Children's Hospital Medical Center, CincinnatiNo longer availableNeuroblastoma | Pheochromocytoma | ParagangliomaUnited States
-
Jubilant DraxImage Inc.RecruitingNeoplasms | Neuroectodermal Tumors | NeuroblastomaUnited States
-
University of California, San FranciscoNational Cancer Institute (NCI)CompletedNeuroblastomaUnited States
-
Cellectar Biosciences, Inc.RecruitingMultiple Myeloma | Waldenstrom Macroglobulinemia | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Chronic Lymphocytic Leukemia | Lymphoplasmacytic Lymphoma | Diffuse Large B Cell Lymphoma | Small Lymphocytic Lymphoma | Central Nervous System LymphomaUnited States, Australia, Czechia, Greece, Israel, Brazil, Finland, France, Spain, Turkey, United Kingdom
-
Cellectar Biosciences, Inc.Active, not recruitingOsteosarcoma | Ewing Sarcoma | Neuroblastoma | Rhabdomyosarcoma | Pediatric Brain Tumor | DIPG | Pediatric Solid Tumor | Pediatric LymphomaUnited States, Australia, Canada
-
Cellectar Biosciences, Inc.National Cancer Institute (NCI)RecruitingHigh-Grade GliomaUnited States, Canada